Cytori Therapeutics Inc (CYTX) Downgraded by Zacks Investment Research
Zacks Investment Research cut shares of Cytori Therapeutics Inc (NASDAQ:CYTX) from a hold rating to a sell rating in a report released on Thursday.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
A number of other equities research analysts have also weighed in on CYTX. B. Riley restated a neutral rating on shares of Cytori Therapeutics in a research report on Sunday, July 30th. Maxim Group set a $5.00 price objective on Cytori Therapeutics and gave the stock a buy rating in a research report on Friday, August 11th. Finally, ValuEngine lowered Cytori Therapeutics from a sell rating to a strong sell rating in a research report on Tuesday, August 1st.
Shares of Cytori Therapeutics (NASDAQ CYTX) opened at $0.37 on Thursday. Cytori Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.13.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.04 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. During the same quarter in the previous year, the company posted ($0.26) EPS. research analysts predict that Cytori Therapeutics will post -0.67 EPS for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sabby Management LLC grew its position in shares of Cytori Therapeutics by 28.0% in the 2nd quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 355,504 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Cytori Therapeutics by 81.9% in the 2nd quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares during the last quarter. Finally, Perkins Capital Management Inc. grew its position in shares of Cytori Therapeutics by 99.0% in the 2nd quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock valued at $962,000 after buying an additional 435,217 shares during the last quarter. Hedge funds and other institutional investors own 12.02% of the company’s stock.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.